Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 10-Q

 

 

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For Quarterly Period Ended December 31, 2018

September 30, 2019

Or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From               to

               

Commission File Number 0-14602

 

CYANOTECH CORPORATION

(Exact name of registrant as specified in its charter)

NEVADA

91-1206026

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification Number)

 

73-4460 Queen Kaahumanu Hwy. #102, Kailua-Kona, HI 96740

(Address of principal executive offices)

 

(808) 326-1353

(Registrant’s telephone number)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.02 par value per share

CYAN

NASDAQ

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): 

Large accelerated filer ☐

  

Accelerated filer ☐

Non-accelerated filer ☐

  

Smaller reporting company ☒

 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

 

As of February 12,November 7, 2019, the number of shares outstanding of the registrant’s sole class of common stock par value $0.02 per share, was 5,836,110.5,917,511.

 

1

Table of Contents

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Report and other presentations made by Cyanotech Corporation (“CYAN”) and its subsidiary contain “forward-looking statements,” which include statements that are predictive in nature, depend upon or refer to future events or conditions, and usually include words such as “expects,” “anticipates,” “intends,” “plan,” “believes,” “predicts”, “estimates” or similar expressions. In addition, any statement concerning future financial performance, ongoing business strategies or prospects and possible future actions are also forward-looking statements. Forward-looking statements are based upon current expectations and projections about future events and are subject to risks, uncertainties and the accuracy of assumptions concerning CYAN and its subsidiary (collectively, the “Company”), the performance of the industry in which CYAN does business, and economic and market factors, among other things. These forward-looking statements are not guarantees of future performance. You should not place undue reliance on forward-looking statements.

 

Forward-looking statements speak only as of the date of the Report, presentation or filing in which they are made. Except to the extent required by the Federal Securities Laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Our forward-looking statements in this Report include, but are not limited to:

 

Statements relating to our business strategy;

 

Statements relating to our business objectives; and

 

Expectations concerning future operations, profitability, liquidity and financial resources.

 

These forward-looking statements are subject to risk, uncertainties and assumptions about us and our operations that are subject to change based on various important factors, some of which are beyond our control, including those factors described in Item 2 of Part I of this quarterly report and in Item 1A of Part I of the Company’s annual report on Form 10-K filed on June 15, 2018.July 1, 2019. Additionally, the following factors, among others, could cause our financial performance to differ significantly from the goals, plans, objectives, intentions and expectations expressed in our forward-looking statements:

 

The added risks associated with or attributed to the current local, national and world economic conditions, including but not limited to, the volatility of crude oil prices, inflation and currency fluctuations;

 

Access to available and reasonable financing on a timely basis;

 

The Company’s inability to generate enough revenues to meet its obligations or repay maturing indebtedness;

 

Failure of capital projects to operate as expected or meet expected results;

 

It is not possible to predict or identify all potential risks and uncertainties and the above referenced factors and list do not comprise a complete list of all potential risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in any forward-looking statement contained in this report. All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, Cyanotech Corporation, together with its subsidiaries,subsidiary, are referred to as “the Company.”

 

2

Table of Contents

 

CYANOTECH CORPORATION

FORM 10-Q

INDEX

 

PART I.  FINANCIAL INFORMATION

  

  

  

Item 1.

Financial Statements

4

  

Condensed Consolidated Balance Sheets as of December 31, 2018September 30, 2019 and March 31, 20182019 (unaudited)

4

  

Condensed Consolidated Statements of Operations for the three and ninesix months ended December 31,September 30, 2019 and 2018 and 2017 (unaudited)

5

 

Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended September 30, 2019 and 2018 (unaudited)

6

Condensed Consolidated Statements of Cash Flows for the ninethree and six months ended December 31,September 30, 2019 and 2018 and 2017 (unaudited)

67

  

Notes to Condensed Consolidated Financial Statements (unaudited)

78

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

2220

Item 4.

Controls and Procedures

2225

  

  

  

PART II.  OTHER INFORMATION

  

  

  

Item 1.

Legal Proceedings

2427

Item 1A

Risk Factors

2427

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

2427

Item 3.

Defaults upon Senior Securities

2427

Item 5.

Other Information

2427

Item 6.

Exhibits

2528

 

 

 

SIGNATURES

2629

 

3

Table of Contents

 

PART I.  FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

 

 

December 31,
2018

  

March 31,
2018

  

September 30,
2019

  

March 31,
2019

 

ASSETS

                

Current assets:

                

Cash

 $1,573  $1,329  $1,094  $840 

Accounts receivable, net of allowance for doubtful accounts of $27 at December 31, 2018 and $27 at March 31, 2018

  1,883   2,664 

Accounts receivable, net of allowance for doubtful accounts of $13 at September 30, 2019 and $27 at March 31, 2019

  1,655   1,982 

Inventories, net

  10,112   9,034   11,129   11,274 

Prepaid expenses and other current assets

  641   590   448   496 

Total current assets

  14,209   13,617   14,326   14,592 
                

Equipment and leasehold improvements, net

  15,183   15,734   13,867   14,752 

Restricted cash

     65 

Operating lease right-of-use assets, net

  3,983    

Other assets

  291   291   261   282 

Total assets

 $29,683  $29,707  $32,437  $29,626 
                

LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable

 $4,055  $3,527  $2,838  $4,922 

Accrued expenses

  1,073   892   834   992 

Customer deposits

  304   626 

Operating lease obligations, current portion

  304    

Short-term contract obligation

  332      54   285 

Line of credit

  1,750   500   2,000   2,000 

Current maturities of long-term debt

  663   655   673   663 

Customer deposits

  172   133 

Total current liabilities

  8,045   5,707   7,007   9,488 
                

Long-term debt, less current maturities

  5,328   5,790   6,349   5,172 

Long-term operating lease obligations

  3,679    

Other long-term liabilities

  57   103   58   57 

Total liabilities

  13,430   11,600   17,093   14,717 
                

Commitments and contingencies

                
                

Stockholders’ equity:

                

Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding

            

Common stock of $0.02 par value, shares authorized 50,000,000; 5,836,110 shares issued and outstanding at December 31, 2018 and 5,772,032 shares at March 31, 2018

  117   115 

Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 5,913,421 shares at September 30, 2019 and 5,879,710 shares at March 31, 2019

  118   117 

Additional paid-in capital

  32,318   32,051   32,786   32,447 

Accumulated deficit

  (16,182

)

  (14,059

)

  (17,560

)

  (17,655

)

Total stockholders’ equity

  16,253   18,107   15,344   14,909 

Total liabilities and stockholders’ equity

 $29,683  $29,707  $32,437  $29,626 

 

See accompanying Notesnotes to Condensed Consolidated Financial Statements.condensed consolidated financial statements

 

4

Table of Contents

 

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

 

Three Months Ended
December 31,

  

Nine Months Ended
December 31,

  

Three Months Ended
September 30,

  

Six Months Ended
September 30,

 
 

2018

  

2017

  

2018

  

2017

  

2019

  

2018

  

2019

  

2018

 
                                

NET SALES

 $10,044  $9,150  $24,143  $26,014 

COST OF SALES

  5,928   4,910   15,906   14,551 

Net sales

 $7,690  $6,954  $15,761  $14,099 

Cost of sales

  4,627   4,669   9,023   9,978 

Gross profit

  4,116   4,240   8,237   11,463   3,063   2,285   6,738   4,121 
                                

OPERATING EXPENSES:

                

Operating expenses:

                

General and administrative

  1,337   1,368   4,190   4,132   1,157   1,481   3,188   2,853 

Sales and marketing

  2,068   1,620   5,088   4,549   1,343   1,597   2,751   3,020 

Research and development

  216   142   635   433   154   211   341   419 

Total operating expenses

  3,621   3, 130   9,913   9,114   2,654   3,289   6,280   6,292 
                                

Income (loss) from operations

  495   1,110   (1,676

)

  2,349   409   (1,004

)

  458   (2,171

)

                                

Interest expense, net

  (134

)

  (130

)

  (414

)

  (371

)

  (182

)

  (150

)

  (367)  (280

)

                                

Income(loss) before income taxes

  361   980   (2,090

)

  1,978 

Income (loss) before income taxes

  227   (1,154

)

  91   (2,451

)

                                

INCOME TAX EXPENSE (BENEFIT)

  73   (127

)

  33   (105

)

Income tax benefit

  (1

)

  (18

)

  (4)  (40

)

                                

NET INCOME (LOSS)

 $288  $1,107  $(2,123

)

 $2,083 

Net income (loss)

 $228  $(1,136

)

 $95  $(2,411

)

                                

NET INCOME (LOSS) PER SHARE:

                

Net income (loss) per share:

                

Basic

 $0.05  $0.19  $(0.37

)

 $0.36  $0.04  $(0.20

)

 $0.02  $(0.42

)

Diluted

 $0.05  $0.19  $(0.37

)

 $0.36  $0.04  $(0.20

)

 $0.02  $(0.42

)

                                

SHARES USED IN CALCULATION OF NET INCOME (LOSS) PER SHARE:

                

Shares used in calculation of net income (loss) per share:

                

Basic

  5,836   5,749   5,809   5,714   5,965   5,806   5,942   5,796 

Diluted

  5,862   5,831   5,809   5,774   5,973   5,806   5,963   5,796 

 

See accompanying Notesnotes to Condensed Consolidated Financial Statements.condensed consolidated financial statements

 

5

Table of Contents

 

CYANOTECH CORPORATION

 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 (Unaudited)

Three months ended September 30, 2019 and 2018

  

Common
Stock
Shares

  

Common
Stock

Amount

  

Additional
Paid-in
Capital

  

Accumulated
Deficit

  

Total
Stockholders’
Equity

 
  

(in thousands, except per share data)

 

Balances at June 30, 2019

  5,889,582  $118  $32,774  $(17,788

)

 $15,104 

Issuance of common stock for exercise of stock options for cash

  2,112             

Issuance of vested shares of restricted stock

  7,483      (7

)

     (7

)

Shares withheld for tax payments

  (2,538

)

            

Settlement agreement with former executive

  16,782      (1

)

     (1

)

Share based compensation expense

        20      20 

Net income

           228   228 

Balances at September 30, 2019

  5,913,421  $118  $32,786  $(17,560

)

 $15,344 
                     

Balances at June 30, 2018

  5,788,887  $116  $32,070  $(15,334

)

 $16,852 

Issuance of common stock for director stock grants

  47,223   1   169      170 

Share based compensation expense

        41      41 

Net loss

           (1,136

)

  (1,136

)

Balances at September 30, 2018

  5,836,110  $117  $32,280  $(16,470

)

 $15,927 

Six months ended September 30, 2019 and 2018

  

Common
Stock
Shares

  

Common
Stock

Amount

  

Additional
Paid-in
Capital

  

Accumulated
Deficit

  

Total
Stockholders’
Equity

 
  

(in thousands, except per share data)

 

Balances at March 31, 2019

  5,879,710  $117  $32,447  $(17,655

)

 $14,909 

Issuance of common stock for exercise of stock options for cash

  2,112      4      4 

Issuance of vested shares of restricted stock

  22,502   1   (26

)

     (25

)

Shares withheld for tax payments

  (7,685

)

            

Settlement agreement with former executive

  16,782      320      320 

Share based compensation expense

        41      41 

Net income

           95   95 

Balances at September 30, 2019

  5,913,421  $118  $32,786  $(17,560

)

 $15,344 
                     

Balances at March 31, 2018

  5,772,032  $115  $32,051  $(14,059

)

 $18,107 

Issuance of common stock for director stock grants

  47,223   1   169      170 

Issuance of common stock for exercise of stock options for cash

  6,000   1   18      19 

Issuance of vested shares of restricted stock

  16,003      (32

)

     (32

)

Shares withheld for tax payments

  (5,148

)

            

Share based compensation expense

        74      74 

Net loss

           (2,411

)

  (2,411

)

Balances at September 30, 2018

  5,836,110  $117  $32,280  $(16,470

)

 $15,927 

See accompanying notes to condensed consolidated financial statements

6

Table of Contents

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(Unaudited)

 

 

Nine Months Ended
December 31,

  

Six Months Ended
September 30,

 
 

2018

  

2017

  

2019

  

2018

 
                

CASH FLOWS FROM OPERATING ACTIVITIES:

                

Net (loss) income

 $(2,123

)

 $2,083 

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

        

Net income (loss)

 $95  $(2,411

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

        

Depreciation and amortization

  1,421   1,403   971   950 

Amortization of debt issue costs and other assets

  34   39 

Amortization of operating leases right-of-use assets

  144    

Share-based compensation expense

  282   369   361   244 

Amortization of debt issue costs and other assets

  57   52 

Net (increase) decrease in assets:

                

Accounts receivable

  781   (791

)

  327   782 

Inventories

  (1,078

)

  (1,730

)

  145   (1,405

)

Prepaid expenses and other assets

  (84

)

  (86

)

  51   (139

)

Net increase (decrease) in liabilities:

                

Accounts payable

  528   (76

)

  (2,084

)

  768 

Accrued expenses

  181   332   (158

)

  (81

)

Customer deposits

  39   (80

)

  (322

)

  (50

)

Other long-term liabilities

  (46

)

  (8

)

Net cash (used in) provided by operating activities

  (42

)

  1,468 

Operating lease obligations

  (144

)

   

Deferred rent and other liabilities

  1   (10

)

Net cash used in operating activities

  (579

)

  (1,313

)

                

CASH FLOWS FROM INVESTING ACTIVITIES:

                

Investment in equipment and leasehold improvements

  (375

)

  (667

)

  (86

)

  (338

)

Investment in Cellana asset purchase

  (100

)

   

Investment in restricted cash

     (65

)

Net cash used in investing activities

  (475

)

  (732

)

  (86

)

  (338

)

                

CASH FLOWS FROM FINANCING ACTIVITIES:

                

Net draws (payments) on line of credit

  1,250   (111

)

Payments on short term contract obligation

  (63

)

     (231

)

   

Payments on capitalized leases

  (49

)

  (67

)

Net draws on line of credit

     1,250 

Proceeds from long-term debt - related party

  1,500    

Principal payments on long-term debt

  (429

)

  (394

)

  (297

)

  (284

)

Proceeds from long-term debt, net of costs

     166 

Withholding on restricted stock unit vesting

  (32

)

   

Proceeds from stock options exercised

  19   26 

Net cash provided by (used in) financing activities

  696   (380

)

Payments on finance leases

  (32

)

  (33

)

Shares withheld for tax payments

  (25

)

  (32

)

Proceeds from exercise of stock options

  4   19 

Net cash provided by financing activities

  919   920 
                

Net increase in cash

  179   356 
        

Net increase (decrease) in cash

  254   (731

)

Cash and restricted cash at beginning of period

  1,394   1,407   840   1,394 
        

Cash at end of period

 $1,573  $1,763 

Cash and restricted cash at end of period

 $1,094  $663 
                

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

                

Cash paid during the period for:

                

Interest

 $358  $313  $337  $219 

Income taxes

 $17  $  $  $ 
                

Purchase of Cellana assets

 $495,000  $ 

Less: Issuance of short-term obligation

  395,000    

Cash paid to acquire Cellana assets

 $100,000  $ 

RECONCILIATION OF CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD:

        

Cash

 $840  $1,329 

Restricted cash

     65 

Total cash and restricted cash at beginning of period

 $840  $1,394 

 

See accompanying Notesnotes to Condensed Consolidated Financial Statements.condensed consolidated financial statements  

 

67

Table of Contents

 

CYANOTECH CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018September 30, 2019

(Unaudited)

 

 

1.

ORGANIZATION AND BASIS OF PRESENTATION

 

Cyanotech Corporation (the “Company”), located in Kailua-Kona, Hawaii, was incorporated in the state of Nevada on March 3, 1983 and is listed on the NASDAQ Global SelectCapital Market under the symbol “CYAN”. The Company is engaged in the production of natural products derived from microalgae for the nutritional supplements market.

 

The Company is an agricultural company that produces high value natural products derived from microalgae grown in complex and intricate open-pond agricultural systems on the Kona coast of Hawaii.  The Company's products include Hawaiian Spirulina Pacifica, a superfood with numerous benefits, including boosting the immune system and overall cellular health; and Hawaiian BioAstin, a powerful antioxidant shown to support and maintain the body's natural inflammatory response.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the instructions to Form 10-Q10-Q and Regulation S-XS-X of the Securities and Exchange Commission (SEC)(“SEC”). These interim condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to present fairly the Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations, Condensed Consolidated Statements of Stockholders' Equity and Condensed Consolidated Statements of Cash Flows for the periods presented in accordance with GAAP.

 

Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full fiscal year. The Condensed Consolidated Balance Sheet as of March 31,2018 2019 was derived from the audited consolidated financial statements. These condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended March 31,2018, 2019, contained in the Company’s annual report on Form 10-K10-K as filed with the SEC on July 1, 2019. 

Liquidity and Capital Resources

As of September 30, 2019, the Company had cash of $1,094,000 and working capital of $7,319,000 compared to $840,000 and $5,104,000, respectively, at March 31, 2019. In April 2019, the Company obtained an unsecured subordinated loan in the amount of $1,500,000 from a related party (see Notes 6 and 13). On August 30, 2016, the Revolving Credit Agreement (the Credit Agreement), which the Company entered into with First Foundation Bank (the Bank) on June 15,2018.3, 2016, became effective. The Credit Agreement allows us to borrow up to $2.0 million on a revolving basis. At September 30, 2019 and March 31, 2019, the Company had outstanding borrowings of $2.0 million on the line of credit.  The line of credit is subject to renewal on August 30, 2020 and the Company intends to renew or replace it with another line of credit on or before the expiration date.

As of September 30, 2019, the Company had $5,547,000 in long-term debt (Term Loans) payable to the Bank that require the payment of principal and interest monthly through August 2032. Pursuant to the Term Loans and the Credit Agreement, the Company is subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of March 31, 2019, the Company’s debt service coverage ratio of -0.66:1 fell short of the Bank's annual requirement of 1.25:1. Additionally, on March 31, 2019, the Company’s current ratio of 1.49:1 fell short of the Bank’s annual requirement of 1.50:1.  On June 17, 2019, the Bank provided the Company with a letter waiving the covenant violations as of March 31, 2019, but noting that the Bank reserved its rights to declare a default in the future if any covenants remain out of compliance at applicable measurement dates.

Funds generated by operating activities and available cash are expected to continue to be the Company’s most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. In the first and second quarter of fiscal year 2020, the Company undertook strategic cost cutting, including the elimination of positions through attrition and the elimination of open positions to create a leaner organization.  Given recent strong astaxanthin production and resulting high inventory levels, the Company also imposed a temporary reduction of astaxanthin production in order to eliminate variable production costs as inventory levels are reduced.

Based upon the Company’s operating plan and related cash flow and financial projections, cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund its operations through at least September 30, 2020, and its debt service coverage ratio and current ratio covenants are expected to be in compliance with the annual Term Loans and Credit Agreement covenant requirements as of March 31, 2020, the next measurement date. However, no assurances can be provided that the Company will achieve its operating plan and cash flow projections for the next fiscal years or its projected consolidated financial position as of March 31, 2020. Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.

8

 

 

2.

SIGNIFICANT ACCOUNTING POLICIES

 

Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. (“Nutrex Hawaii” or “Nutrex”, collectively the “Company”). All intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported.  Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary.  Actual results could differ from those estimates and assumptions.

  

Cash and Restricted Cash

 

The Company considers only its monetary liquid assets with original maturitiesCash primarily consists of three months or less as cash on hand and cash equivalents.in bank deposits. Proceeds from equipment loans are classified as restricted cash until drawn upon. 

The following table provides a reconciliation of cash andThere was no restricted cash reported within the Company's consolidated balance sheets to the total amount presented in the consolidated statementas of cash flows:September 30, 2019 or March 31, 2019.

  

December 31,

2018

  

March 31,

2018

 
  

(in thousands)

 

Cash

 $1,329  $1,407 

Restricted Cash

  65    

Cash and restricted cash at beginning of period

 $1,394  $1,407 
         

Cash

 $1,573  $1,329 

Restricted Cash

     65 

Cash and restricted cash at end of period

 $1,573  $1,394 

7

 

Concentration of Accounts Receivable and RevenuesRisk

 

A significant portion of revenue and accounts receivable are derived from a few major customers. For the three months ended September 30, 2019 and 2018, two customers accounted for 40% and 17%, and 32% and 14%, respectively, of the Company’s net sales. For the six months ended September 30, 2019 and 2018, two customers accounted for 36% and 17, and 34% and 25%, respectively, of the Company’s net sales. At DecemberSeptember 30, 2019 and March 31, 2018, 2019, three customers accounted for 67% and 60%, respectively, of the Company’s accounts receivable was comprised of two customer balances of 43% and 24%, respectively. At March 31, 2018, 76% of the Company’s accounts receivable was comprised of three customer balances of 45%,16% and 15%, respectively. Two customers accounted for 66% of total net sales for the three months ended December 31, 2018, comprised of 35% and 31%, respectively. Two customers accounted for 50% of total net sales for the three months ended December 31, 2017, comprised of 26% and 24%, respectively. Two customers accounted for 62% of total net sales for the nine months ended December 31, 2018, comprised of 35% and 27%, respectively. Two customers accounted for 47% of total net sales for the nine months ended December 31, 2017, comprised of 30% and 17%, respectively.balance.

 

Revenue Recognition

 

The Company records revenue based on the five-stepfive-step model which includes: (1)(1) identifying the contract with the customer; (2)(2) identifying the performance obligations in the contract; (3)(3) determining the transaction price; (4)(4) allocating the transaction price to the performance obligations; and (5)(5) recognizing revenue when the performance obligations are satisfied. Substantially all of the Company’s revenue is generated by fulfilling orders for the purchase of our micro algalmicroalgal nutritional supplements to retailers, wholesalers, or direct to consumers via online channels, with each order considered to be a distinct performance obligation. These orders may be formal purchase orders, verbal phone orders, e-mail orders or orders received online. Shipping and handling activities for which the Company is responsible under the terms and conditions of the order are not accounted for as performance obligations but as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized. The impact of this policy election is insignificant as it aligns with our current practice.

 

Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price.  The impact of this policy election is insignificant, as it aligns with our current practice.  The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts.  Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the products to the customer. Revenue is recognized at the point in time that control of the ordered products is transferred to the customer. Generally, this occurs when the product is delivered, or in some cases, picked up from one of our distribution centers by the customer. Revenue from extraction services is recognized when control is transferred upon completion of the extraction process.

9

 

Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the three-monththree-month periods ended December 31,September 30, 2019 and 2018, and December 31, 2017, the Company recognized $0$6,000 and $20,000,$0, respectively, of revenue from deposits that were included in contract liabilities as of March 31, 2019 and 2018, and March 31, 2017, respectively. During the nine-monthsix-month periods ended December 31,September 30, 2019 and 2018, and December 31, 2017, the Company recognized $114,000$517,000 and $91,000,$114,000, respectively, of revenue from deposits that were included in contract liabilities as of March 31, 2019 and 2018, and March 31, 2017, respectively. The Company’s contracts have a duration of one year or less and therefore, the Company has elected the practical expedient of not disclosing revenues allocated to partially unsatisfied performance obligations.

 

Disaggregation of Revenue

 

The following table represents revenue disaggregatedby major product in the threeline and nine months ended December 31, 2018 and December 31, 2017 (in thousands):extraction services for the:

 

  

Three months ended December 31, 2018

  

Nine months ended December 31, 2018

 
  

Astaxanthin

  

Spirulina

  

Total

  

Astaxanthin

  

Spirulina

  

Total

 

Packaged products

 $6,012  $3,212  $9,224  $15,388  $6,208  $21,596 

Bulk products

  287   533   820   884   1,663   2,547 

Total

 $6,299  $3,745  $10,044  $16,272  $7,871  $24,143 

8

  

Three months ended December 31, 2017

  

Nine months ended December 31, 2017

 
  

Astaxanthin

  

Spirulina

  

Total

  

Astaxanthin

  

Spirulina

  

Total

 

Packaged products

 $5,746  $2,268  $8,014  $15,649  $6,560  $22,209 

Bulk products

  317   819   1,136   748   3,057   3,805��

Total

 $6,063  $3,087  $9,150  $16,397  $9,617  $26,014 

($ in thousands)

 

Three Months

Ended

September 30, 2019

  

Three Months

Ended

September 30, 2018

 

Packaged sales

        

Astaxanthin packaged

 $4,747  $4,281 

Spirulina packaged

  1,731   1,928 

Total packaged sales

  6,478   6,209 
         

Bulk sales

        

Astaxanthin bulk

  328   334 

Spirulina bulk

  744   411 

Total bulk sales

  1,072   745 
         

Contract extraction revenue

  140    

Total net sales

 $7,690  $6,954 

 

Reclassification

($ in thousands)

 

Six Months

Ended

September 30, 2019

  

Six Months

Ended

September 30, 2018

 

Packaged sales

        

Astaxanthin packaged

 $9,357  $9,376 

Spirulina packaged

  3,645   2,996 

Total packaged sales

  13,002   12,372 
         

Bulk sales

        

Astaxanthin bulk

  502   597 

Spirulina bulk

  1,977   1,130 

Total bulk sales

  2,479   1,727 
         

Contract extraction revenue

  280    

Total net sales

 $15,761  $14,099 

 

Certain amounts previously reported in the fiscal 2018 consolidated financial statements have been reclassified to conform with the fiscal 2019 financial presentation. These reclassifications have no impact on net income.

 

Recently Adopted Accounting Pronouncements

 

Effective April 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842): Accounting for Leases and issued subsequent amendments to the initial guidance and implementation guidance including ASU No. 2018-01, 2018-10, 2018-11, 2018-20 and 2019-01 (collectively including ASU No. 2016-02, “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities that are measured at the present value of the future lease payments at lease commencement date. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and shall continue to depend on its classification as a finance or operating lease. The Company elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not restate prior periods. Under the new guidance, the majority of the Company’s leases continue to be classified as operating. Based on the Company’s lease portfolio, the impact of adopting ASC 842 increased both total assets and total liabilities, however, it did not have a significant impact on the Company’s consolidated statements of operations or cash flows. Finance leases continue to be classified with long-term debt on the Condensed Consolidated Balance Sheets and are described in Note 6. See Note 7 for operating leases.

10

In June 2018, the FASB issued ASU 2018-07, “Compensation - Stock Compensation (Topic 718)” (“ASU No. 2018-07”): Improvements to Nonemployee Share-Based Payment Accounting. ASU No. 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU No. 2018-07 is effective for the Company in the first quarter of fiscal year 2020.  The Company adopted ASU No. 2018-07 as of April 1, 2019 with no impact on its consolidated financial statements and related disclosures.

In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09,ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting ("ASU No.2017-09" 2017-09"). ASU No.2017-09 2017-09 will clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance became effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. The amendments in ASU No.2017-09 2017-09 are applied prospectively to awards modified on or after the adoption date. The Company adopted this standard as of April 1, 2018 with no impact on its consolidated financial statements. 

 

In November 2016, the FASB issued ASU 2016-18,2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash” (“ASU No.2016-18” 2016-18”).  This update addresses the fact that diversity exists in the classification and presentation of changes in restricted cash on the statement of cash flows under Topic 230, Statement of Cash Flows. ASU No.2016-18 2016-18 became effective for public companies for the fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this standard as of April 1, 2018 by using the retrospective method, which required reclassification of restricted cash in the accompanying consolidated statement of cash flows as of the beginning of the period for the nine monthsfiscal year ended DecemberMarch 31, 2018. 2017. 

 

In August 2016, FASB issued ASU 2016-15,2016-15,Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU No.2016-15” 2016-15”). ASU No.2016-15 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduces the current diversity in practice. ASU No.2016-15 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The Company adopted this standard as of April 1, 2018 with no impact on its consolidated financial statements and related disclosures.

 

In May 2014, the FASB issued their converged standard on revenue recognition, Accounting Standards Update ASU No.2014-09, 2014-09, Revenue from Contracts with Customers (Topic 606)("ASU No.2014-09" 2014-09”), updated in December 2016 with the release of ASU 2016-20.2016-20. This standard outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods and services in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.  In August 2015, the FASB issued ASU No2015-14 2015-14 Revenue from Contracts with Customers (Topic 606)606): Deferral of the Effective Date," which deferred the effective date of ASU No.2014-09 2014-09 to annual reporting periods beginning after December 15, 2017.

 

The new revenue standard is required to be applied either retrospectively to each prior reporting period presented or prospectively with the cumulative effect of initially applying the standard recognized at the date of the initial application, supplemented with certain disclosures related to the effect of adoption on previously reported amounts, if any (the modified retrospective method). The Company adopted the standard on April 1, 2018 for contracts that were not completed before the adoption date, using the modified retrospective method.  The Company has evaluated the effect of the standard and concluded it is not material to the timing or amount of revenues or expenses recognized in the Company’s historical consolidated financial statements. As a result, the Company has concluded that the application of the standard does not have a material effect that requires a retrospective adjustment to any previously reported amounts in the Company’s historical consolidated financial statements for reporting disclosure purposes.

 

  Recently Issued Accounting Pronouncements

 

In November 2018, the FASB issued ASU 2018-182018-18 – Collaborative Arrangements, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. This ASU will be effective for usthe Company in the first quarter of fiscal 2021 with early adoption permitted. This ASU requires retrospective adoption to the date wethe Company adopted ASC 606,April 1, 2018, by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. The Company is currently evaluating the impact of the adoption of this standard on its financial statements.

 

9

In August 2018, the FASB issued ASU 2018-15,2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU No.2018-15” 2018-15”), which aligns the capitalization requirements for implementation costs incurred in a hosting arrangement that is a service contract with the existing capitalization requirements for implementation costs incurred to develop or obtain internal-use software (Subtopic 350-40). ASU 2018-152018-15 becomes effective for the Company in the first quarter of fiscal 2021 and may be adopted either retrospectively or prospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on its financial statements.

 

11

In August 2018, the FASB issued ASU 2018-13,2018-13, “Fair Value Measurement - Disclosure Framework (Topic 820)” (“ASU No.2018-13” 2018-13”). The updated guidance improves the disclosure requirements on fair value measurements. The updated guidance isbecomes effective for the Company in the first quarter of fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. year 2021. Early adoption is permitted for any removed or modified disclosures. The Company is currently assessing the timing and impact of adopting the updated provisions.

In June 2018, the FASB issued ASU 2018-07,Compensation - Stock Compensation (Topic 718)” (“ASU No.2018-07”): Improvements to Nonemployee Share-Based Payment Accounting. ASU No.2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU No.2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02,Leases (Topic 842)” (ASU No.2016-02”). The principle objective of ASU No.2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet. ASU No.2016-02 continues to retain a distinction between finance and operating leases but requires lessees to recognize a right-of-use asset representing its right to use the underlying asset for the lease term and a corresponding lease liability on the balance sheet for all leases with terms greater than twelve months. ASU No.2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. Early adoption of ASU No.2016-02 is permitted. Entities were required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. This guidance is applicable to the Company’s fiscal year beginning April 1, 2019. In July 2018, the FASB issued ASU 2018-10Codification Improvements to Topic 842, Leases” (“ASU No.2018-02”).  ASU No.2018-02 affects narrow aspects of the guidance issued in the amendments in ASU No.2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under Topic 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under Topic 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions.  In July 2018, the FASB issued ASU No.2018-11, "Leases (Topic 842): Targeted Improvements," which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, the prior comparative period’s financials will remain the same as those previously presented. Entities that elect this optional transition method must provide the disclosures that were previously required. The Company expects it will elect this optional transition method. The Company has selected resources to track and record leases and is starting the assessment and valuation process by evaluating the population of leases under the revised definition of what qualifies as a leased asset, and expects to have the assessment completed by March 2019. The Company is the lessee under various agreements for facilities and equipment that are currently accounted for as operating and capital leases. The Company expects this guidance will have a material impact on its consolidated balance sheets due to the recognition of lease rights and obligations as assets and liabilities, respectively. The Company does not expect this guidance to have a material effect on its consolidated results of operations and cash flows. 

10

Table of Contents

 

 

3.

INVENTORIES

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-outfirst-in, first-out method. Inventories consist of the following:following at:

 

 

December 31,

2018

  

March 31,

2018

  

September 30,

2019

  

March 31,

2019

 
 

(in thousands)

  

(in thousands)

 

Raw materials

 $460  $410  $331  $495 

Work in process

  4,649   2,602   4,104   4,032 

Finished goods

  4,828   5,878   6,483   6,587 

Supplies

  175   144   211   160 

Inventories, net

 $10,112  $9,034  $11,129  $11,274 

 

The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, as an expense in the period incurred. AbnormalThe Company expensed abnormal production costs related to spirulina production of $0$0 and $250,000 were charged$250,000 to cost of sales for the three and ninesix months ended December 31,September 30, 2018, respectively. There were no abnormal production costs for the three and ninesix months ended December 31,2017.September 30, 2019. Non-inventoriable fixed costs related to production of $35,000 (astaxanthin)$85,000 and $176,000 ($35,000 astaxanthin and $141,000 spirulina)$16,000 were chargedexpensed to cost of sales for the three and nine months ended December 31,September 30, 2019 and 2018, respectively. Non-inventoriable fixed costs related to spirulina production of $4,000$100,000 and $88,000$141,000 were chargedexpensed to cost of sales for the three and ninesix months ended December 31,2017,September 30, 2019 and 2018, respectively.

 

 

4.

EQUIPMENT AND LEASEHOLD IMPROVEMENTS

 

Equipment and leasehold improvements consist of the following:following at:

 

 

December 31,

2018

  

March 31,

2018

  

September 30,

2019

  

March 31,

2019

 
 

(in thousands)

  

(in thousands)

 

Equipment

 $18,312  $17,935  $18,767  $18,679 

Leasehold improvements

  14,288   14,248   14,725   14,723 

Furniture and fixtures

  348   348   369   348 
  32,948   32,531   33,861   33,750 

Less accumulated depreciation and amortization

  (18,767

)

  (17,346

)

  (20,216

)

  (19,254

)

Construction-in-progress

  1,002   549   222   256 

Equipment and leasehold improvements, net

 $15,183  $15,734  $13,867  $14,752 

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amount to forecasted undiscounted future cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future cash flows, then an impairment charge is recognized to the extent that the carrying amount exceeds the asset’s fair value. Management has determined no asset impairment existed as of December 31,2018September 30, 2019 and March 31, 2019, respectively. Depreciation and amortization expense were approximately $480,000 and $475,000 for the three months ended September 30, 2019 and 2018, respectively. Depreciation and amortization expense were approximately $971,000 and $950,000 for the six months ended September 30, 2019 and 2018, respectively.

 

 

5.

SHORT TERM CONTRACT OBLIGATION

 

On November 30, 2018 the Company completed the purchase of a six acre production and research facility from Cellana LLC (“Cellana”) under a purchase agreement that was signed August 31, 2018. In accordance with the terms of the third amendment to the asset purchase agreement, the Company acquired the asset for $495,000$495,000 with a cash down payment of $100,000$100,000 leaving a short-term obligation of $395,000$395,000 on the asset purchase.

 

The short -termterm obligation is comprised of two separate loans in the principal amount of $180,000$180,000 and $215,000.$215,000. The first loan of $180,000$180,000 bears an interest rate of 6.25% and iswas payable in four monthly installments which includes principal and interest. The loan commenced on December 1, 2018 and maturesmatured on July 15, 2019. The principal amounts outstanding at September 30, 2019 and March 31, 2019. The principal amount outstanding at December 31, 2018 was $137,000.2019 were $0 and $137,000, respectively.

12

 

The second loan in thehas a principal amount of $215,000$215,000 and is a non-interest bearing loan that is payable in twelve monthly installments comprised of two monthly payments of $10,000$10,000 and ten monthly payments of $19,543.$19,543. The loan commenced on December 1, 2018 and matures on October 15, 2019. This contract contains a hold back of $38,000$38,000 pending resolution of certain closing items by the seller. The principal amountamounts outstanding at DecemberSeptember 30, 2019 and March 31, 2018 was $195,000.2019 were $54,000 and $148,000, respectively.

 

 

6.6.

LINE OF CREDIT AND LONG-TERM DEBT

 

Total debt consists of the following at September 30, 2019 and March 31, 2019:

  

September 30,

2019

  

March 31,

2019

 
  

(in thousands)

 

Line of credit

 $2,000  $2,000 

Long-term debt

  5,706   6,035 

Long-term debt - related party

  1,500    

Less current maturities

  (2,673

)

  (2,663

)

Long-term debt, excluding current maturities

  6,533   5,372 

Less unamortized debt issuance costs

  (184

)

  (200

)

Total long-term debt, net of current maturities and unamortized debt issuance costs

 $6,349  $5,172 

Line of Credit and Term Loans

On August 30, 2016, the Revolving Credit Agreement (the “Credit Agreement”), which the Company and First Foundation Bank (“the Bank”) entered into on June 3, 2016, became effective after the Company and the Bank received the necessary approvals from the State of Hawaii to secure the lien on the Company’s leasehold property in Kona, Hawaii. The Credit Agreement allows the Company to borrow up to $2,000,000$2,000,000 on a revolving basis. Borrowings under the Credit Agreement bear interest at the Wall Street Journal prime rate (5.50%(5.5% at December both September 30, 2019 and March 31,2018) 2019) plus 2%, floating. The

At both September 30, 2019 and March 31, 2019, the outstanding balance under the Credit Agreement includes various covenants as defined in the Credit Agreement. The Credit Agreement also contains standard acceleration provisions in the event of a default by the Company. As of December 31, 2018, the Company had borrowed $1,750,000 and had $250,000 available on the line.was $2,000,000. The line of credit, which is subject to annual renewal, and was renewed on August 30, 2018 2019 and will be subject to renewal upon expiration on August 30, 2019. 2020. Pursuant to the August 30, 2018 2019 renewal, the current ratio covenant was changed from 2.10:1 to 1.50:1 and is applicable to both the Lineline of Creditcredit and Long-Term Debtterm loans with the Bank.

11

 

The Credit Agreement grants the Bank the following security interests in the Company’s property: (a) a lien on the Company’s leasehold interest in its Kona facility; (b) an assignment of the Company’s interest in leases and rents on its Kona facility; and (c) a security interest in all fixtures, furnishings and equipment related to or used by the Company at the Kona facility. Each security interest is further subject to the terms of the Credit Agreement.

7.

ACCRUED EXPENSES

 

Accrued expenses consist of the following:

 

 

December 31,

2018

 

 

March 31,

2018

 

 

 

(in thousands)

 

Wages, commissions, bonus and profit sharing

 

$

799

 

 

$

707

 

Other accrued expenses

 

 

274

 

 

 

185

 

Total accrued expenses

 

$

1,073

 

 

$

892

 

8.

LONG-TERM DEBT

Long-term debt consists of the following:

  

December 31,

2018

  

March 31,

2018

 
  

(in thousands)

 

Long-term debt

 $6,101  $6,530 

Capital lease obligations

  98   148 

Less current maturities

  (663

)

  (655

)

Long-term debt, excluding current maturities

  5,536   6,023 

Less unamortized debt issuance costs

  (208

)

  (233

)

Total long-term debt, net of current maturities and unamortized debt issuance costs

 $5,328  $5,790 

Term Loans

On August 14, 2012, In 2015, the Company entered intoexecuted a loan agreement with a lender providing for $2,500,000 in aggregate credit facilities (the “August 2012 “2015 Loan”) secured by substantially all the Company’s assets, pursuant to a Term Loan Agreement dated July 30, 2015 (the “2015 Loan Agreement”) that provides. The 2015 Loan is evidenced by a term loanpromissory note in an aggregate principalthe amount of $5,500,000$2,500,000, the repayment of which is partially guaranteed under the provisions of the United States Department of Agriculture (“USDA”) Rural Development Guarantee program. The proceeds of the 2015 Loan were used to pay off a $500,000 short term note payable that matured on September 18, 2015, and to acquire new processing equipment and leasehold improvements at the Company’s Kona, Hawaii facility.

 The provisions of the 2015 Loan require the payment of principal and interest until its maturity on September 1, 2022; the obligation fully amortizes over seven (7) years. Interest on the 2015 Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (5.5% at September 30, 2019 and March 31, 2019) plus 2.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter. At no time shall the annual interest rate be less than 6.0%. The 2015 Loan has a prepayment penalty of 5.0% for any prepayment made prior to the first anniversary of the date of the 2015 Loan Agreement, which penalty is reduced by 1.0% each year thereafter until the fifth anniversary of such date, after which there is no prepayment penalty. The balance under the 2015 Loan was $1,212,000 and $1,389,000 at September 30, 2019 and March 31, 2019, respectively, and was included in long-term debt in the debt table above.

In 2012, the Company executed a loan agreement with a lender providing for $5,500,000 in aggregate credit facilities (the “2012 Loan”) secured by substantially all the Company’s assets, including a mortgage on the Company's interest in its lease at the National Energy Laboratory of Hawaii Authority.Authority, pursuant to a Term Loan Agreement dated August 14, 2012 (the “2012 Loan Agreement”). The August 2012 Loan Agreementis evidenced by promissory notes in the amounts of $2,250,000 and $3,250,000, the repayment of which is partially guaranteed under the provisions of the U.S. Department of Agriculture (“USDA”)a USDA Rural Development Guarantee program.Guarantee. The proceeds of the 2012 Loan were used to acquire processing equipment and leasehold improvements at its Kona, Hawaii facility.

 

13

In accordance with terms

The provisions of the August 2012 Loan Agreement, monthly paymentsrequired the payment of principalinterest only for the first 12 months of the term; thereafter, and interest are required until the loan’sits maturity on August 14,2032. 2032, the obligation fully amortizes over nineteen (19) years. Interest on the loan2012 Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (5.50%(5.5% at December September 30, 2019 and March 31,2018) 2019) plus 1.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter. At no time shall the annual interest rate be less than 5.50%5.5%. The balance under the August 2012 Loan Agreement was $4,492,000$4,335,000 and $4,648,000$4,439,000 at DecemberSeptember 30, 2019 and March 31, 2018 2019, respectively, and March 31,2018, respectively.was included in long-term debt in the debt table above.

  

The 2015 Loan includes a one-timeone-time origination and guaranty feesfee totaling $214,500$113,900 and an annual renewal fee payable in the amount of 0.25%0.5% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year, beginning December 31,2012. 2015. The USDA has guaranteed 80% of all amounts owing under the August2015 Loan. The 2012 Loan Agreement. The Company is subject to financial covenants and customary affirmative and negative covenants.  

On July 30, 2015, the Company entered intoincluded a loan agreement (the “2015 Loan Agreement”) that provides a term loan in an aggregate principal amount of $2,500,000 and is secured by all the Company’s assets. The 2015 Loan Agreement is partially guaranteed under the provisions of the USDA Rural Development Guarantee program.

In accordance with terms in the 2015 Loan Agreement, payment of principal and interest are required until its maturity on September 1,2022. Interest on the loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (5.50% at December 31,2018) plus 2.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter.

12

 The 2015 Loan includes a one-timeone-time origination and guaranty feefees totaling $113,900$214,500 and an annual renewal fee payable in the amount of 0.50%0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year, beginning December 31,2015. 2012. The USDA has guaranteed 80% of all amounts owing under the 20152012 Loan. The Company isbalance in unamortized debt issuance costs was $184,000 and $200,000 at September 30, 2019 and March 31, 2019.

Loan Covenant Violations and Waiver

The Company’s Credit Agreement, 2015 Loan and 2012 Loan are subject to annual debt service and other financial covenants, including covenants which require the Company to meet key financial ratios and customary affirmative and negative covenants.  As of March 31, 2019, the Company was not in compliance with the required debt service coverage ratio or the current ratio and due to these violations, the Bank would be contractually entitled to require immediate repayment of the outstanding term loan amounts of $5,828,000 and the outstanding line of credit balance of $2,000,000.  However, on June 17, 2019, the bank issued the Company a letter waiving the covenant violations as of March 31, 2019.  The outstanding balance of the terms loans is presented as a non-current liability at September 30, 2019 and March 31, 2019.

 

At no time shallLong-term Debt – Related Party

In April 2019, the annualCompany obtained an unsecured subordinated loan in the amount of $1,500,000.  Interest accrues at a rate of 6.5% and is payable quarterly.  The principal amount and any accrued and unpaid interest rate be less than 6.00%are due in April 2021 (see Note 13). The 2015 Loan Agreement has a prepayment penalty of 5% for any prepayment made prior to the first anniversary of the date of the loan and each year thereafter the penalty is reduced by 1% each year until the fifth anniversary of such date when there will no longer be a prepayment penalty.  The balance under the 2015 Loanthis loan was $1,500,000 at September 30, 2019.

 Equipment Finance Agreement was $1,475,000 and $1,726,000 at December 31, 2018 and March 31,2018, respectively.

 

On October 6, 2017, the Company entered into an Equipment Finance Agreement (the “Equipment Agreement”), with a lender, which provides up to $175,000$175,000 of financing for equipment. The interest rate on this loan is 4.75%. In accordance with terms in The provisions of the Equipment Agreement require the payment of principleprincipal and interest are required until its maturity on October 31, 2022. The balance under this loan was $134,000$110,000 and $156,000$126,000 at December 31, 2018 September 30, 2019 and March 31, 2018, respectively. 2019, respectively, and was included in long-term debt in the debt table above.

 

Capital Leases Finance Lease Obligations

 

TheIn August 2016, the Company has three capital leasesexecuted a finance lease agreement with Thermo Fisher Financial providing for $278,000$52,000 in equipment, secured by the equipment financed. The capital leases mature at various dates between finance lease matured in May 2019 and March 2021 and arewas payable in 60 equal monthly payments, except for one which is payable in 36 equal monthly payments. The interest ratesrate under thesethis capital leases range from 4.18% to lease was 12.90%. The aggregate balancesbalance under these leases were $98,000this lease was $0 and $148,000$7,800 at December 31,2018September 30, 2019 and March 31, 2018, respectively.2019, respectively, and was included in long-term debt in the debt table above.

In February 2016, the Company executed a finance lease agreement with Bank of the West providing for $51,000 in equipment, secured by the equipment financed. The finance lease matures in March 2021 and is payable in 60 equal monthly payments. The interest rate under this finance lease is 4.18%. The balance under this lease was $16,000 and $22,000 at September 30, 2019 and March 31, 2019, respectively, and was included in long-term debt in the debt table above.

In July 2015, the Company executed a finance lease agreement with Huntington Technology Finance providing for $174,000 in equipment, secured by the equipment financed. The finance lease matures in July 2020 and is payable in 60 equal monthly payments. The interest rate under this lease is 6.57%. The balance under this lease was $33,000 and $52,000 at September 30, 2019 and March 31, 2019, respectively, and was included in long-term debt in the debt table above.

14

 

Future principal payments under the loans and finance lease obligations at September 30, 2019 are as follows:

Payments Due

 

(in thousands)

 

Remainder of 2020

 $336 

2021

  676 

2022

  2,202 

2023

  468 

2024

  279 

Thereafter

  3,245 

Total principal payments

 $7,206 

 

9.7.

OPERATING LEASES

The Company leases it facilities, equipment and land under non-cancelable operating leases expiring through 2037. Right-of-use assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Right-of-use assets and liabilities were recognized at April 1, 2019 based on the present value of lease payments over the lease term, using the Bank’s incremental borrowing rate based on the information available. At September 30, 2019, the weighted average remaining lease terms is 13.5 years, the weighted average discount rate is 7.5% and the operating lease costs are $296,000.

Supplemental balance sheet information related to leases at September 30, 2019 is as follows:

Operating leases

 

Balance Sheet Classification

 

(in thousands)

 

Right-of-use assets

 

Operating lease right-of-use assets, net

 $3,983 
       

Current lease liabilities

 

Operating lease obligations

 $304 

Non-current lease liabilities

 

Long-term operating lease obligations

  3,679 

Total lease liabilities

 $3,983 

Maturities of lease liabilities at September 30, 2019 are as follows:

Payments

 

(in thousands)

 

Remainder of 2020

 $591 

2021

  595 

2022

  592 

2023

  426 

2024

  371 

Thereafter

  3,878 

Total undiscounted lease payments

  6,453 

Less: present value discount

  (2,470

)

Total lease liability balance

 $3,983 

8.

ACCRUED EXPENSES

Accrued expenses consist of the following:

  

September 30,

2019

  

March 31,

2019

 
  

(in thousands)

 

Wages, commissions, bonus and profit sharing

 $206  $145 

Vacation

  274   338 

Severance

  141   153 

Rent, interest and legal

  83   235 

Other accrued expenses

  130   121 

Total accrued expenses

 $834  $992 

15

9.

COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may be involved in litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. 

On October 2, 2019, a shareholder of the Company, Meridian OHC Partners, LP (“Meridian”), filed a complaint in the United States District Court, District of Hawaii, against the Board of Directors seeking to proceed derivatively on behalf of the Company.  The Company believesis named as a nominal defendant.  The complaint alleges, among other things, that it currentlythe directors have breached their fiduciary duties, in overseeing the Company.  Meridian seeks declaratory and injunctive relief and an award of damages to the Company.  The case is not a party toMeridian v. Davis et al. (Cyanotech), No. 19-cv-0536 (D. Hawaii).  The probability and magnitude of any legal proceedings or claims which, individually or in aggregate, would have a material effect on its consolidated financial position, results of operations or cash flows.potential loss cannot be estimated at this time.

 

 

 

10.10.

SHARE-BASED COMPENSATION

 

The Company has share-based compensation plans, which are more fully described in Note 9,10, Share-Based Compensation, to the Consolidated Financial Statements included in the Company’s annual report on Form 10-K10-K for the year ended March 31, 2019 as filed with the SEC on June 15, 2018.July 1, 2019.

 

As of December 31,2018,September 30, 2019, the Company had two equity-based compensation plans: the 2016 Equity Incentive Plan (the “2016“2016 Plan”) and the 2014 Independent Director Stock Option and Restricted Stock Grant Plan (the “2014“2014 Directors Plan”). The Company has also issued stock options, which remain outstanding as of December 31, 2018, September 30, 2019, under two equity-based compensation plans which have expired according to their terms: the 2005 Stock Option Plan (the “2005“2005 Plan”) and the 2004 Independent Director Stock Option and Stock Grant Plan (the “2004“2004 Directors Plan”). These plans allowed the Company to award stock options and shares of restricted common stock to eligible employees, certain outside consultants and independent directors. No additional awards will be issued under the 2005 Plan or the 2004 Directors Plan. 

 

The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans:

 

As of December 31, 2018

Authorized

Available

Outstanding

2016 Plan

1,300,0001,113,022170,975

2014 Directors Plan

350,000184,40012,000

2005 Plan

434,400

2004 Directors Plan

12,000

Total

1,650,0001,297,422629,375

13

  

As of September 30, 2019

 
  

Authorized

  

Available

  

Outstanding

 
             

2016 Plan

  1,300,000   1,067,935   191,580 

2014 Directors Plan

  350,000   184,400   116,724 

2005 Plan

        261,800 

2004 Directors Plan

        12,000 

Total

  1,650,000   1,252,335   582,104 

 

Stock Options

 

All stock option grants made under the equity-based compensation plans were issued at exercise prices no less than the Company’s closing stock price on the date of grant,grant. Options under the 2016 Plan, 2005 Plan and 2014 Directors Plan were determined by the Board of Directors or the Compensation Committee of the Board of Directors in accordance with the provisions of the respective plans.  The terms of each option grant include vesting, exercise, and other conditions set forth in a Stock Option Agreement evidencing each grant. No option can have a life in excess of ten (10) (10) years. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. The model requires various assumptions, including a risk-free interest rate, the expected term of the options, the expected stock price volatility over the expected term of the options, and the expected dividend yield. Compensation expense for employee stock options is recognized ratably over the vesting term. Compensation expense recognized for options issued under all Plans was $18,000$5,000 and $54,000$18,000 for the three and nine months ended December 31,September 30, 2019 and 2018, respectively. Compensation expense recognized for options issued under all Plans was $13,000$118,000 and $47,000$36,000 for the three and ninesix months ended December 31,2017,September 2019 and 2018, respectively. All stock-basedIn the first six months of fiscal year 2020, compensation has been classified as general and administrative expense in the condensed consolidated statementincluded $109,000 related to a settlement agreement with a former executive.

16

 

A summary of option activity under the Company’s stock plans for the ninesix months ended December 31,2018September 30, 2019 is presented below: 

 

Option Activity

 

Shares

  

Weighted
Average
Exercise

Price

  

Weighted

Average
Remaining
Contractual
Term (in

years)

  

Aggregate
Intrinsic
Value

  

Shares

  

Weighted
Average
Exercise

Price

  

Weighted

Average
Remaining
Contractual
Term (in

years)

  

Aggregate
Intrinsic
Value

 

Outstanding at March 31, 2018

  589,400  $4.06   4.9  $675,300 

Outstanding at March 31, 2019

  539,800  $4.06   4.7  $15,480 

Granted

    $             $         

Exercised

  (6,000

)

 $2.85           (2,112

)

 $2.08         

Forfeited

  (5,000

)

 $5.75           (81,888

)

 $4.41         

Outstanding at December 31, 2018

  578,400  $4.06   4.2  $43,804 

Exercisable at December 31, 2018

  483,400  $4.15   3.3  $43,804 

Outstanding at September 30, 2019

  455,800  $4.01   2.5  $ 

Exercisable at September 30, 2019

  405,800  $4.14   1.7  $ 

 

The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company’s closing stock price of $3.02 for such day.$2.59 and $3.24 at September 30, 2019 and March 31, 2019, respectively.

 

A summary of the Company’s non-vested options for the ninesix months ended December 31,2018September 30, 2019 is presented below:

 

Nonvested Options

 

Shares

  

Weighted
Average
Grant-Date
Fair Value

 

Nonvested at March 31, 2018

  120,000  $1.81 

Granted

      

Vested

  (25,000

)

  1.71 

Forfeited

      

Nonvested at December 31, 2018

  95,000  $1.83 

Nonvested Options

 

Shares

  

Weighted
Average
Grant-Date
Fair Value

 

Nonvested at March 31, 2019

  130,000  $1.70 

Vested

  (80,000

)

  1.81 

Nonvested at September 30, 2019

  50,000  $1.52 

 

As of December 31,2018,September 30, 2019, total unrecognized stock-based compensation expense related to all unvested stock options was $127,000,$61,000, which is expected to be expensed over a weighted average period of 1.63.3 years.

Subsequent to December 31, 2018, 50,000 stock options were granted from the 2016 Plan at an exercise price of $3.00 per share.

Restricted Stock

There were no grants of fully vested restricted stock issued to Non-Employee Directors for the three months ended December 31, 2018 and December 31, 2017. Grants of fully vested restricted stock issued to Non-Employee Directors was 47,223 shares and 57,501 shares for the nine months ended December 31, 2018 and December 31, 2017, respectively. Compensation expense recognized for fully vested restricted stock was $0 and $170,000 for the three and nine months ended December 31, 2018, respectively. Compensation expense recognized for fully vested restricted stock was $0 and $276,000 for the three and nine months ended December 31, 2017, respectively.

 

Restricted Stock Units (“RSUs”) 

 

RSUs are service-based awards granted to eligible employees under the 2016 Plan. Compensation expense recognized for RSUs issued under the 2016 Plan was $20,000$14,000 and $58,000$16,000 for the three and nine months ended December 31,September 30, 2019 and 2018, respectively. Compensation expense recognized for RSUs issued under the 2016 Plan was $15,000$37,000 and $48,000$32,000 for the three and ninesix months ended December 31, 2017, September 30, 2019 and 2018, respectively.

14

Table  In the first six months of Contents

On July 13, 2018, 22,449 RSUs were awardedfiscal 2020, compensation expense included $6,000 related to employees of the Company. This award is valued at $4.0252 per share, the closing market price of the Company’s common stock on the grant date, and vests over a period of two years. settlement agreement with a former executive.

 

The following table summarizes information related to awarded RSUs: RSUs for the six months ended September 30, 2019:

 

Nonvested Restricted Stock Units

 

Shares

  

Weighted
Average
Grant Price

  

Shares

  

Weighted
Average
Grant Price

 

Nonvested restricted stock units at March 31, 2018

  39,675  $3.89 

Nonvested restricted stock units at March 31, 2019

  38,814  $3.98 

Granted

  23,923   4.10   4,051   2.67 

Vested

  (7,670

)

  3.92   (16,149

)

  3.71 

Forfeited

  (4,953

)

  4.08   (5,136

)

  4.02 

Nonvested restricted stock units at December 31, 2018

  50,975  $3.97 

Nonvested restricted stock units at September 30, 2019

  21,580  $3.93 

 

As of December 31,2018,September 30, 2019, total unrecognized stock-based compensation expense related to unvested restricted stock units was $140,000,$52,000, which is expected to be expensed over a weighted average period of 1.81.1 years.

Common Stock

In the first six months of fiscal 2020, the Company recorded $205,000 in compensation expense related to a settlement agreement with a former executive.

17

Table of Contents

 

 

11.11.

INCOME TAXES

 

On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 34% to 21% effective January 1, 2018. The Company will compute its income tax expense for the March 31, 2019 fiscal year using a21% Federal Tax Rate of 21%. The 21% Federal Tax Rate will applyapplies to fiscal years ending March 31, 2019 and each year thereafter. The Company completed the accounting for the income tax effects of the Tax Act as of March 31, 2018 and determined that the amount identified as provisional in the quarter ended December 31, 2017 was a materially correct amount. As a result, no measurement period adjustments have been recorded.

 

We utilize ourThe Company utilizes its estimated annual effective tax rate to determine ourits provision (benefit)or benefit for income taxes for interim periods. The income tax provision (benefit)or benefit is computed by multiplying the estimated annual effective tax rate by the year to date pre-tax book income (loss). WeThe Company recorded an income tax expensebenefit of $73,000$1,000 and ($127,000)$18,000 for the three months ended December 31,September 30, 2019 and 2018, and 2017,respectively. WeThe Company recorded an income tax expense of $33,000 and income tax benefit of ($105,000)$4,000 and $40,000 for the ninesix months ended December 31,September 30, 2019 and 2018, and 2017,respectively. OurThe Company’s effective tax rate was 20.2%0.2% and (1.6%) for the three and nine months ended December 31,2018, respectively,September 30, 2019 and (13.0%2018, respectively. The Company’s effective tax rate was (3.8%) and (5.3%)1.6% for the three and ninesix months ended December 31,2017,September 30, 2019 and 2018, respectively. The effective tax raterates for the three and ninesix months ended December 31,September 30, 2019 and 2018 differsdiffer from the statutory rate of 21% as a result of state taxes (net of federal benefit) and the net change in valuation allowance against the net deferred tax asset the Company believes is not more likely than not to be realized.  The Company continues to carry a full valuation allowance on its net deferred tax assets.

 

The Company is subject to taxation in the United States and six state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities.  As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

 

As of December 31,September 30, 2019 and 2018, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its consolidated condensed statements of operations, which is consistent with the recognition of these items in prior reporting periods.

  

With few exceptions, the Company is no longer subject to U.S. federal, state, local, and non-U.S. income tax examination by tax authorities for tax years before 2013.2014.

15

Table of Contents

 

 

12.12.

EARNINGS(LOSS) PER SHARE

 

Basic earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding. Diluted earnings per share is computed on the basis of the weighted average number of common shares outstanding plus the potentially dilutive effect of outstanding stock options using the “treasury stock” method.

 

Reconciliations between the numerator and the denominator of the basic and diluted earningsincome (loss) per share computations for the three and six months ended December 31,2018September 30, 2019 and 20172018 are as follows:

 

 

Three Months Ended December 31, 2018

  

Three Months Ended September 30, 2019

 
 

Net Loss

  

Shares

  

Per Share

  

Net Income

  

Shares

  

Per Share

 
 

(Numerator)

  

(Denominator)

  

Amount

  

(Numerator)

  

(Denominator)

  

Amount

 
 

(in thousands)

      

(in thousands)

     

Basic income per share

 $288   5,836  $0.05  $228   5,965  $0.04 

Effect of dilutive securities — Common stock options

     26    

Effective dilutive securities – restricted stock units

     8    

Diluted income per share

 $288   5,862  $0.05  $228   5,973  $0.04 

 

  

Three Months Ended December 31, 2017

 
  

Net Income

  

Shares

  

Per Share

 
  

(Numerator)

  

(Denominator)

  

Amount

 
  

(in thousands)

     
             

Basic income per share

 $1,107   5,749  $0.19 

Effect of dilutive securities — Common stock options

     82    

Diluted income per share

 $1,107   5,831  $0.19 
18

Table of Contents

  

Three Months Ended September 30, 2018

 
  

Net Loss

  

Shares

  

Per Share

 
  

(Numerator)

  

(Denominator)

  

Amount

 
  

(in thousands)

     
             

Basic and diluted loss per share

 $(1,136

)

  5,806  $(0.20

)

  

Six Months Ended September 30, 2019

 
  

Net Loss

  

Shares

  

Per Share

 
  

(Numerator)

  

(Denominator)

  

Amount

 
  

(in thousands)

     

Basic income per share

 $95   5,942  $0.02 

Effective dilutive securities – restricted stock units

     21    

Diluted income per share

 $95   5,963  $0.02 

  

Six Months Ended September 30, 2018

 
  

Net Loss

  

Shares

  

Per Share

 
  

(Numerator)

  

(Denominator)

  

Amount

 
  

(in thousands)

     
             

Basic and diluted loss per share

 $(2,411

)

  5,796  $(0.42

)

 

Reconciliations between the numerator and the denominator of the basic

Basic and diluted (loss) earnings per share computations foramounts are the nine months ended December 31,2018 and 2017same in periods of a net loss, because common share equivalents are as follows:

  

Nine Months Ended December 31, 2018

 
  

Net Loss

  

Shares

  

Per Share

 
  

(Numerator)

  

(Denominator)

  

Amount

 
  

(in thousands)

     

Basic and diluted loss per share

 $(2,123

)

  5,809  $(0.37

)

  

Nine Months Ended December 31, 2017

 
  

Net Income

  

Shares

  

Per Share

 
  

(Numerator)

  

(Denominator)

  

Amount

 
  

(in thousands)

     

Basic income per share

 $2,083   5,714  $0.36 

Effect of dilutive securities—Common stock options

     60    

Diluted income per share

 $2,083   5,774  $0.36 

Potentially dilutive securities include 75,000 outstanding options to purchase common stock for the three and nine months ended December 31, 2018 and 20,991 restricted stock units for the three and nine months ended December 31, 2018. anti-dilutive when a net loss is recorded. Diluted earnings per share does not include the impact of 75,000 options to purchase common stock options totaling 75,000 and 120,000 for the three month period and six months ended December 31,September 30, 2018, as the effect of their inclusion would be anti-dilutive. As a result of the net loss for the nine month period ended December 31, 2018, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Diluted earnings per share does not include the impact of 75,000 options to purchase common stock for the three and nine month period ended December 31, 2017, respectively, as the effect of their inclusion would be anti-dilutive. Restricted stock units become dilutive within the period granted and remain dilutive until the units vest and are issued as common stock. Diluted earnings per share does not include the impact of restricted stock units totaling 23,000 for both the three and six months ended September 30, 2018, as the effect of their inclusion would be anti-dilutive.

 

 

13.13.

RELATED PARTY TRANSACTIONS AND BALANCES

 

During the ninesix months ended December 31,September 30, 2018, the Company entered into a consulting agreement with an effective date of May 5, 2018 with a vendor that employs one of our independent directors.  The Company’s independent director is not named in or involved in the performance of the consulting agreement. The contract amount of $120,000 isthe contract was for $120,000 and all the payments made against the contract were reflected in general and administrative expense duringexpense.

During the ninesix months ended December 31, 2018 September 30, 2019, the Company obtained an unsecured subordinated loan from Skywords Family Foundation, Inc. (“Skywords”) in the principal amount of $1,500,000 pursuant to a Promissory Note (“the Skywords Note”) executed by the Company in favor of Skywords. Skywords is controlled by the Company’s Chairman of the Board of Directors and $120,000largest stockholder. The Skywords Note bears interest at a rate of 1% plus the prime rate (as published by the Wall Street Journal), which will be recalculated and payable on a quarterly basis. The principal amount and any accrued and unpaid interest will be due and payable on April 12, 2021, unless accelerated in payments have been made againstan event of default. The Company may prepay the contract duringSkywords Note at any time without penalty. The proceeds of the nine months ended December 31, 2018.  Skywords Note were used to pay down accounts payable and for general operating capital purposes.

 

1619

Table of Contents

 

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview:

 

We are a world leader in the production of high value natural products derived from microalgae. Incorporated in 1983, we are guided by the principle of providing beneficial, quality microalgal products for health and human nutrition in a sustainable, reliable and environmentally sensitive operation. We are GMP (Good Manufacturing Practices) certified by the Natural Products Association™, reinforcing our commitment to quality in our products, quality in our relationships (with our customers, suppliers, employees and the communities we live in), and quality of the environment in which we work. Our products include:

 

Hawaiian BioAstin® natural astaxanthin - a powerful dietary antioxidant shown to support and maintain the body’s natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient; and

 

Hawaiian Spirulina Pacifica® - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids

 

Microalgae are a diverse group of microscopic plants that have a wide range of physiological and biochemical characteristics and contain, among other things, high levels of natural protein, amino acids, vitamins, pigments and enzymes. Microalgae have the following properties that make commercial production attractive: (1) microalgae grow much faster than land grown plants, often up to 100 times faster; (2) microalgae have uniform cell structures with no bark, stems, branches or leaves, permitting easier extraction of products and higher utilization of the microalgae cells; and (3) the cellular uniformity of microalgae makes it practical to control the growing environment in order to optimize a particular cell characteristic. Efficient and effective cultivation of microalgae requires consistent light, warm temperatures, low rainfall and proper chemical balance in a very nutrient-rich environment, free of environmental contaminants and unwanted organisms. This is a challenge that has motivated us to design, develop and implement proprietary production and harvesting technologies, systems and processes in order to commercially produce human nutritional products derived from microalgae.

 

Our production of these products at the 96-acre facility on the Kona Coast of the island of Hawaii provides several benefits. We selected the Keahole Point location in order to take advantage of relatively consistent warm temperatures, sunshine and low levels of rainfall needed for optimal cultivation of microalgae. This location also offers us access to cold deep ocean water, drawn from an offshore depth of 2,000 feet, which we use in our Ocean-Chill Drying system to eliminate the oxidative damage caused by standard drying techniques and as a source of trace nutrients for microalgal cultures. The area is also designated a Biosecure Zone, with tight control of organisms allowed into the area and free of genetically modified organisms (GMO’s). We believe that our technology, systems, processes and favorable growing location generally permit year-round harvest of our microalgal products in a cost-effective manner.

 

Results of Operations

 

The following tables present selected consolidated financial data for each of the periods indicated ($ in thousands):

 

 

Three Months Ended

  

Nine Months Ended

  

Three Months Ended

  

Six Months Ended

 
 

December 31,

  

December 31,

  

September 30,

  

September 30,

 
 

2018

  

2017

  

2018

  

2017

  

2019

  

2018

  

2019

  

2018

 

Net sales

 $10,044  $9,150  $24,143  $26,014  $7,690  $6,954  $15,761  $14,099 

Net sales increase (decrease)

  9.8

%

      (7.2

)%

    

Net sales increase

  10.6

%

      11.8

%

    

Gross profit

 $4,116  $4,240  $8,237  $11,463  $3,063  $2,285  $6,738  $4,121 

Gross profit as % of net sales

  41.0

%

  46.3

%

  34.1

%

  44.1

%

  39.8

%

  32.9

%

  42.8

%

  29.2

%

Operating expenses

 $3,621  $3,130  $9,913  $9,114  $2,654  $3,289  $6,280  $6,292 

Operating expenses as % of net sales

  36.0

%

  34.2

%

  41.1

%

  35.0

%

  34.5

%

  47.2

%

  39.8

%

  44.6

%

Operating income (loss)

 $495  $1,110  $(1,676

)

 $2,349  $409  $(1,004

)

 $458  $(2,171

)

Operating income (loss) as % of net sales

  4.9

%

  12.1

%

  (6.9

)%

  9.0

%

  5.3

%

  (14.4

)%

  2.9

%

  (15.4

)%

Income tax expense (benefit)

 $73  $(127

)

 $33  $(105

)

Income tax benefit

 $(1

)

 $(18

)

 $(4

)

 $(40

)

Net income (loss)

 $288  $1,107  $(2,123

)

 $2,083  $228  $(1,136

)

 $95  $(2,411

)

 

1720

Table of Contents

 

Comparison of the Three Months Ended DecSeptemberember 31, 30, 2019 and 2018 and 2017

 

Net Sales (in thousands)

 

Three Months Ended

          

Three Months Ended

         
 

December 31,

  

$

  

%

  

September 30,

  $  

%

 
 

2018

  

2017

  

Change

  

Change

  

2019

  

2018

  

Change

  

Change

 

Packaged sales

                                

Astaxanthin

 $6,012  $5,746  $266   4.6

%

 $4,747  $4,281  $466   10.9

%

Spirulina

  3,212   2,268   944   41.6

%

  1,731   1,928   (197

)

  (10.2

)%

Total Packaged sales

 $9,224  $8,014  $1,210   15.0

%

 $6,478  $6,209  $269   4.3

%

                                

Bulk sales

                                

Astaxanthin

 $287  $317  $(30

)

  (9.5

)%

 $328  $334  $(6

)

  (1.8

)%

Spirulina

  533   819   (286

)

  (34.9

)%

  744   411   333   81.0

%

Total Bulk sales

 $820  $1,136  $(316

)

  (27.8

)%

 $1,072  $745  $327   43.9

%

                                

Contract extraction revenue

 $140  $  $140   100

%

                

Total sales

                                

Astaxanthin

 $6,299  $6,063  $236   3.9

%

 $5,075  $4,615  $460   10.0

%

Spirulina

  3,745   3,087   658   21.3

%

  2,475   2,339   136   5.8

%

Contract extraction revenue

  140      140   100

%

Total sales

 $10,044  $9,150  $894   9.8

%

 $7,690  $6,954  $736   10.6

%

 

Net SalesThe net sales increase of 9.8%10.6% for the current quarter compared to the same period last year was primarily driven by highera 10.9% increase in astaxanthin packaged sales, an 81.0% increase in spirulina bulk sales, (up 21.3%)as well as an increase in contract extraction services. The increase compared to prior year was a result of a lack of available product in the prior year and contract extraction services that began at the end of fiscal 2019. The increase was offset by a decrease of 1.8% in astaxanthin bulk sales and 10.2% in spirulina packaged sales, primarily due to a 16% improvementreduction in spirulina production over the same periodsales to one of our major customers in the prior year. This resulted in a 41.6% increase in packaged spirulina sales offset by a 34.9% decrease in bulk spirulina sales. The decrease in bulk spirulina sales is attributed to the lack of inventory available for bulk customers. One customer made up 84% of the $0.7 million increase in packaged spirulina sales, this occurred in October 2018 with orders placed to build customers inventory. International sales represented 9% of net sales for the current quarter comparedrelated to 24% for the same period last year. International sales were negatively impacted by the lacktiming of spirulina inventory available for bulk customers.their orders.

 

Gross Profit Our grossGross profit margin for the current quarter decreased 5.3as a percent of net sales increased by 6.9 percentage points compared to the same period last year, primarily due to increasedthe improvements in production costs for both spirulina and astaxanthin cost resulting from an 18% reduction in astaxanthin production asthe current year compared to the same three month period in theexcessive prior year.year costs.

 

Operating Expenses Operating expenses increased $0.5decreased $0.6 million for the current quarter compared to the same period in last year. General and administrative expenses remained consistent with the same period of the prior year.  Salesyear, primarily due to strategic cost cutting initiatives, including lower promotional and marketing expenses increased $0.4spending of $0.3 million, dueand timing difference in stock grants to a $0.5 million increase in advertising and promotion costs, offset by a $0.1 million decrease in outside services expense. Research and development expenses increased $0.1 million duethe Board of Directors from the second fiscal quarter to a reallocationthe third fiscal quarter of personnel resulting from changes in responsibilities.$0.2 million.

 

 Income Taxes We recorded income tax expensebenefit of $0.1 million$1,000 for the thirdsecond quarter of this fiscal year with an effective tax rate of 20.2%,0.2% compared to an income tax benefit of $0.1 million$18,000 for the same period last year with an effective tax rate of (13.0%)1.6%Income tax expense for the quarter included a discrete tax expense of approximately $15,000 as a result of greater state tax expense and greater AMT credit benefit than was originally estimated in our tax provision for our fiscal year ended March 30, 2018. This increased the effective tax rate for this quarter by 4.1%.WeWe continue to carry a full valuation allowance on our net deferred tax assets.

 

1821

Table of Contents

 

Comparison of the NineSix Months Ended December 31,September 30, 2019 and 2018 and 2017

 

Net Sales (in thousands)

 

Nine Months Ended

          

Six Months Ended

         
 

December 31,

  

$

  

%

  

September 30,

  $  

%

 
 

2018

  

2017

  

Change

  

Change

  

2019

  

2018

  

Change

  

Change

 

Packaged sales

                                

Astaxanthin

 $15,388  $15,649  $(261

)

  (1.7

)%

 $9,357  $9,376  $(19

)

  (0.2

)%

Spirulina

  6,208   6,560   (352

)

  (5.4

)%

  3,645   2,996   649   21.7

%

Total Packaged sales

 $21,596  $22,209  $(613

)

  (2.8

)%

 $13,002  $12,372  $630   5.1

%

                                

Bulk sales

                                

Astaxanthin

 $884  $748  $136   18.2

%

 $502  $597  $(95

)

  (15.9

)%

Spirulina

  1,663   3,057   (1,394

)

  (45.6

)%

  1,977   1,130   847   75.0

%

Total Bulk sales

 $2,547  $3,805  $(1,258

)

  (33.1

)%

 $2,479  $1,727  $752   43.5

%

                                

Contract extraction revenue

 $280  $  $280   100

%

                

Total sales

                                

Astaxanthin

 $16,272  $16,397  $(125

)

  (0.8

)%

 $9,859  $9,973  $(114

)

  (1.1

)%

Spirulina

  7,871   9,617   (1,746

)

  (18.2

)%

  5,622   4,126   1,496   36.3

%

Contract extraction revenue

  280      280   100

%

Total sales

 $24,143  $26,014  $(1,871

)

  (7.2

)%

 $15,761  $14,099  $1,662   11.8

%

 

Net SalesThe net sales decreaseincrease of 7.2%11.8% for the first ninesix months of fiscal 20192020 compared to the same period last year was primarily driven by a 36.3% increase in spirulina sales in both packaged and bulk sales, as well as an 18.2%increase in contract extraction services. The increase compared to prior year was a result of a lack of available spirulina product in the prior year and contract extraction services that began at the end of fiscal 2019. The increase was offset by a slight decrease of 1.1% in astaxanthin sales, primarily due to a reduction in sales to one of our spirulina due to lower supply that was the result of the complete re-inoculation that took placemajor customers in the first quartersix months of this fiscal year. International sales represented 14%2020 related to the timing of net sales for the current quarter compared to 23% for the same period last year. International sales were negatively impacted by the lack of spirulina inventory available for bulk customers.their orders.

 

Gross Profit Our grossGross profit margin for the first ninesix months of fiscal 2019 decreased 10.02020 as a percent of net sales increased by 13.6 percentage points compared to the same period last year, primarily due primarily to the improvements in production costs for both spirulina re-inoculation and the resulting decrease in supply. The lower spirulina production levels in both Q4 of fiscal 2018 (-63% compared to Q4 of fiscal 2017) and in Q1 of the current fiscal year (-76% compared to Q1 of fiscal 2018) has had a negative impact on our year-to-date performance. In addition to decreased sales volume, the lower production levels resulted in a $1.4 million increase in cost of goods and reduced gross profit margin by 5.8 percentage points for the first nine months of the current fiscal year. The 15% reduction in astaxanthin production resulted in a $0.8 million reduction in gross profit, or 3.3 percentage points, as compared to the prior.astaxanthin.

 

Operating Expenses Operating expenses increased $0.8were $6.3 million for both the first ninesix months of fiscal 2019 compared2020 and fiscal 2019. In the current year, overall costs were down due to the same periodcost cutting initiatives, which were offset by increases in last year. Generalgeneral and administrative expenses remained consistent with the same period of the prior year.  Sales and marketing expenses increasedrelated to $0.5 million due toof severance for a $0.9 million increase in advertising and promotion costs, offset by a $0.4 million decrease in outside services expense. Research and development expenses increased $0.2 million due to a reallocation of personnel resulting from changes in responsibilities.former executive.

 

 Income Taxes We recorded income tax expensebenefit of $33,000$4,000 for the first ninesix months of this yearfiscal 2020 with an effective tax rate of 1.6%,(3.8%) compared to an income tax benefit of $105,000$40,000 for the same period last year with an effective tax rate of (5.3%)1.6%Income tax expense for the first nine months of this year included a discrete tax expense of approximately $15,000 as a result of greater state tax expense and greater AMT credit benefit than was originally estimated in our tax provision for our fiscal year ended March 30, 2018. This reduced the effective tax rate for this period by 0.7%.WeWe continue to carry a full valuation allowance on our net deferred tax assets.

 

Liquidity and Capital Resources

 

As of December 31, 2018,September 30, 2019, we had cash of $1.6$1.1 million and working capital of $6.2$7.3 million compared to $1.3$0.8 million and $7.9$5.1 million, respectively, at March 31, 2018.2019.  In April 2019, we obtained an unsecured subordinated loan in the amount of $1,500,000 from a related party (see Notes 6 and 13 in the notes to condensed consolidated financial statements).  On August 30, 2016, the Revolving Credit Agreement (the Credit Agreement), which we andentered into with First Foundation Bank (the Bank) entered into on June 3, 2016, became effective. The Credit Agreement allows us to borrow up to $2.0 million on a revolving basis. At September 30, 2019 and March 31, 2019, we had outstanding borrowings of $2.0 million on the line of credit. The line of credit was renewedis subject to renewal on August 30, 20182020 and will expirewe intend to renew or replace it with another line of credit on August 30, 2019. At December 31, 2018, we had borrowed $1.75 million and had $0.25 million available onor before the line. Along with the renewal, the bank reduced the current ratio requirement on the credit line and all term loans to 1.50:1; the former requirement was 2.10:1.expiration date.

 

As of December 31, 2018,September 30, 2019, we had $6.0$5.5 million of term loansin long-term debt (Term Loans) payable to the Bank that require the payment of principal and interest monthly through August 2032. Pursuant to the term loans,Term Loans and the Credit Agreement, we are subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. We were in compliance with these financial covenants atAs of March 31, 2018.2019, our debt service coverage ratio of -0.66:1 fell short of the Bank's annual requirement of 1.25:1. Additionally, on March 31, 2019, our current ratio of 1.49:1 fell short of the Bank’s annual requirement of 1.50:1.  On June 17, 2019, the Bank provided us with a letter waiving the covenant violations as of March 31, 2019, but noting that the Bank reserved its rights to declare a default in the future if any covenants remain out of compliance at applicable measurement dates.

 

1922

Table of Contents

 

Funds generated by operating activities and available cash are expected to continue to be our most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. In the first quarter of fiscal year 2020, we undertook strategic cost cutting, including the elimination of positions through attrition and the elimination of open positions to create a leaner organization.  Given recent strong astaxanthin production and resulting high inventory levels, we also imposed a temporary reduction of astaxanthin production in order to eliminate variable production costs as inventory levels are reduced.

Based upon our fiscal year 2019 operating plan and related cash flow projections and our projected consolidated financial position as of March 31, 2019,projections, cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund our operations forthrough at least the next twelve months,September 30, 2020, and our debt service coverage ratio and current ratio iscovenants are expected to be in compliance with the annual term loanTerm Loans and Credit Agreement covenant requirementrequirements as of March 31, 2019.2020, the next measurement date. However, no assurances can be provided that we will achieve our operating plan and cash flow objectivesprojections for the next fiscal year ended March 31, 2019years or our projected consolidated financial position as of March 31, 2019.2020. Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.

 

Cash Flows The following table summarizes our cash flows for the periods indicated ($ in thousands):

 

 

Nine months ended

December 31

  

Six months ended

September 30

 
 

2018

  

2017

  

2019

  

2018

 

Total cash provided by (used in):

                

Operating activities

 $(42

)

 $1,468  $(579

)

 $(1,313

)

Investing activities

  (475

)

  (732

)

  (86

)

  (338

)

Financing activities

  696   (380

)

  919   920 
                

Increase in cash

 $179  $356 

Increase (decrease) in cash

 $254  $(731

)

 

Cash used in operating activities for the ninesix months ended December 31, 2018September 30, 2019 was the result of a net loss, offset byincome, non-cash charges of $1.8$2.0 million, andoffset by a decrease in working capitalaccounts payable of $2.1 million and lower customer deposits of $0.3 million. The decrease in working capital was primarily the result of a $1.1 million increase in inventory, offset by a $0.5 million increase in accounts payable and a $0.8 million decrease in accounts receivable. The $1.1 million increase in inventory is comprised primarily of a $0.9 million increase in spirulina inventory and related nutrient supplies, and a $0.3 million increase in astaxanthin inventory.

 

Cash used in investing activities for the ninesix months ended December 31, 2018September 30, 2019 includes costs for leasehold improvementsequipment and equipment acquisitionsfurniture and fixtures at our Kona facility, including the cash payment for the purchase of assets from Cellana LLC.facility.

 

Cash provided by financing activities for the ninesix months ended December 31, 2018September 30, 2019 consists primarily of a $1.3$1.5 million increase in our line of creditfrom the new loan from the long-term debt - related party loan, offset by $0.06 principal payments made on the short-term contract obligation to acquire the Cellana assetsof short term obligations and by the $0.5 million in principal payments on debt in the normal course of business. The line of credit advance was used to fund operations during the re-inoculation period and is expected to be repaid through cash flow from operating activities in future quarters.long-term debt.

 

Sources and Uses of Capital

 

At December 31, 2018,September 30, 2019, our working capital was $6.2$7.3 million, a decreasean increase of $1.7$2.2 million compared to March 31, 2018.2019. The decreaseincrease is due primarily to an increasea decrease in short term debt and accounts payable.payables.

  

Our results of operations and financial condition can be affected by numerous factors, many of which are beyond our control and could cause future results of operations to fluctuate materially as it has in the past. Future operating results may fluctuate as a result of changes in sales volumes to our largest customers, weather patterns, increased competition, increased materials, nutrient and energy costs, government regulations and other factors beyond our control.

  

A significant portion of our expense levels are relatively fixed, so the timing of increases in expenses is based in large part on forecasts of future sales. If net sales are below expectations in any given period, the adverse impact on results of operations may be magnified by our inability to adjust spending quickly enough to compensate for the sales shortfall. We may also choose to reduce prices or increase spending in response to market conditions, which may have a material adverse effect on financial condition and results of operations.

  

Based upon our current operating plan, analysis of our consolidated financial position and projected future results of operations, we believe that our operating cash flows, cash balances and working capital will be sufficient to finance current operating requirements, debt service requirements, and routine planned capital expenditures, for the next twelve (12) months.

 

2023

Table of Contents

 

Outlook 

 

This outlook section contains a number of forward-looking statements, all of which are based on current expectations. Actual results may differ materially.

 

Our strategic direction has been to position the Company as a world leader in the production and marketing of high-value natural products from microalgae. We are vertically aligned, producing raw materials in the form of microalgae processed at our 96-acre facility in Hawaii, and integrating those raw materials into finished products. In fiscal 2019,2020, our primary focus is on buildingstabilizing our consumer brands, increasing our astaxanthin production volume, rationalizing market channel participation, executing on our strategic cost cutting programs, and improving the consistencyleveraging our centers of our production for both astaxanthin and spirulina.core competence. We will continue to putplace emphasis on our Nutrex HawaiiHawaiian consumer products while exploring further opportunities for bulk sales orders for Spirulina and Astaxanthin, both domestically and internationally. Extraction services to introduce them3rd party customers utilizing our 1,000 bar super critical CO2 extractor process are expected to a broader consumer market, andgenerate additional income throughout the year. We will leverage our experience and reputation for quality, building nutritional brandsproducts which promote health and well-being. The foundation of our nutritional products is naturally cultivated Hawaiian Spirulina Pacifica® in powder and tablet form; and BioAstin® Hawaiian Astaxanthin® antioxidant in extract and softgel form. Information about our Company and our products can be viewed at www.cyanotech.com and www.nutrex-hawaii.com. Consumer products can also be purchased online at www.nutrex-hawaii.com.

 

We are focused on sustainability of production levels in order to promote growth in our astaxanthin and spirulina product lines. We will continue to improve and expand these lines to meet the demand of consumers. Our recent re-inoculation of our spirulina ponds was a necessary step toward sustaining long-term production levels.  We will continue to promote the nutritional superiority of Hawaiian grown microalgae to maintain and expand market share. Significant sales variability between periods and even across several periods can be expected based on historical results.

Gross profit margin percentages going forward willcan be impacted by lower production volumes and continuedalong with pressure on input costs andas well as greater competition in the market place. This could cause margins to decline in future periods. We will continue to focus on higher margin consumer products that promote health and well-being. We are dedicated towell-being and strive for continuous improvements in processprocesses and production methods to stabilize costs and increase production levels for the future. However, significant sales variability between periods may occur based on historical results.

 

Producing the highest quality microalgae is a complex biological process which requires balancing numerous factors including microalgal strain variation, temperature, acidity, nutrient and other environmental considerations, some of which are not within our control. An imbalance or unexpected event can occur resulting in production levels below normal capacity. The allocation of fixed production overheads (such as depreciation, rent and general insurance) to inventories is determined based on normal production capacity. When our production volumes are below normal capacity limits, certain fixed production overhead costs cannot be inventoried and are recorded immediately in cost of sales. In addition, when production costs exceed historical averages, we evaluate whether such costs are one-time-period charges or an ongoing component of inventory cost.

  

To manage our cash resources effectively, we will continue to balance production in light ofwith sales demand, minimizing the cost associated with build-ups in inventory levels when appropriate.appropriate and manage our expenses judiciously. We could experience unplanned cash outflows and may need to utilize other cash resources to meet working capital needs. A prolonged downturn in sales could impair our ability to generate sufficient cash for operations and minimizehamper our ability to attract additional capital investment which could become necessary in order to expand facilities, enter into new markets or maintain optimal production levels.levels and efficiencies.

 

Our future results of operations and the other forward-looking statements contained in this Outlook, in particular the statements regarding revenues, gross margin and capital spending, involve a number of risks and uncertainties. In addition to the factors discussed above, any of the following could cause actual results to differ materially: business conditions and growth in the natural products industry and in the general economy; changes in customer order patterns; changes in demand for natural products in general; changes in weather conditions; changes in health and growing conditions of our astaxanthin and spirulina products; competitive factors, such as increased production capacity from competing spirulina and astaxanthin producers and the resulting impact, if any, on world market prices for these products; government actions and increased regulations both domestic and foreign; shortage of manufacturing capacity; and other factors beyond our control. Risk factors are discussed in detail in Part II, Item 1A of this quarterly report and in Part I, Item 1A of our Form 10-K report for the year ended March 31, 2018.2019.

  

We believe that our technology, systems, processes and favorable growing location generally permit year-round harvest of our microalgal products in a cost-effective manner. However, previously experienced imbalances in the highly complex biological production systems, together with volatile energy costs and rapidly changing world markets, suggest a need for continuing caution with respect to variables beyond our reasonable control. Therefore, we cannot, and do not attempt to, provide any definitive assurance with regard to our technology, systems, processes, location, or cost-effectiveness.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2018,September 30, 2019, we had no off-balance sheet arrangements or obligations.

 

2124

Table of Contents

 

Impact of Inflation

 

Inflationary factors such as increases in the costs of materials and labor directly affect the Company'sour operations. Most of the Company'sour leases provide for cost-of-living adjustments and require itus to pay for insurance and maintenance expenses, all of which are subject to inflation. Additionally, the Company’sour future lease cost for new facilities may include potentially escalating costs of real estate and construction. There is no assurance that the Companywe will be able to pass on increased costs to itsour customers.

 

Depreciation expense is based on the historical cost to the Company of its fixed assets and is therefore potentially less than it would be if it were based on current replacement cost. While property and equipment acquired in prior years will ultimately have to be replaced at higher prices, it is expected that replacement will be a gradual process over many years.

 

Critical Accounting Policies and Estimates

 

Our critical accounting policies and estimates are disclosed in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the fiscal year ended March 31, 20182019 filed with the SEC on June 15, 2018.July 1, 2019. In the ninesix months ended December 31, 2018,September 30, 2019, there were changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K related to the adoption of ASU 2014-09 on April 1, 2018, as described below.

 

Effective April 1, 2019, we adopted ASU 2016-02, Revenue RecognitionLeases (Topic 842): Accounting for Leases

and issued subsequent amendments to the initial guidance and implementation guidance including ASU 2018-01, 2018-10, 2018-11, 2018-20 and 2019-01 (collectively including ASU 2016-02, “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities that are measured at the present value of the future lease payments at lease commencement date. The Company records revenue basedrecognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and shall continue to depend on its classification as a finance or operating lease. We elected the five-step model which includes: (1) identifying the contract with the customer; (2) identifying the performance obligationsoptional transition method that allows for a cumulative-effect adjustment in the contract; (3) determiningperiod of adoption and did not restate prior periods. Under the transaction price; (4) allocatingnew guidance, the transaction price to the performance obligations; and (5) recognizing revenue when the performance obligations are satisfied. Substantially all of the Company’s revenue is generated by fulfilling orders for the purchasemajority of our micro algal nutritional supplements to retailers, wholesalers, or direct to consumers via online channels, with each order consideredleases continue to be a distinct performance obligation. These orders may be formal purchase orders, verbal phone orders, e-mail orders or orders received online. Shipping and handling activities for which the Company is responsible under the terms and conditions of the order are not accounted forclassified as performance obligations but as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized. The impact of this policy election is insignificant as it aligns withoperating. Based on our current practice.

Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price.  The impact of this policy election is insignificant, as it aligns with our current practice. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts.  Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period andlease portfolio, the impact of any adjustments are recognizedadopting ASC 842 increased both total assets and total liabilities, however, it did not have a significant impact on our consolidated statements of operations or cash flows. Finance leases continue to be classified with long-term debt on the Condensed Consolidated Balance Sheets. See Note 6 and 7 in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intentnotes to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the products to the customer.condensed consolidated financial statement.

 

Revenue is recognized at the point in time that the control of the ordered products is transferred to the customer. Generally, this occurs when the product is delivered, or in some cases, picked up from one of our distribution centers by the customer.

Item 3.   Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes to our market risk during the nine months ended December 31, 2018. For additional information, refer to our Annual Report on Form 10-K for the year ended March 31, 2018.

Item 4.    Controls and Procedures 

Controls and Procedures

 

Disclosure Controls and Procedures 

 

Under the supervision and with the participation of our management, including our chief executive officer (“CEO”) and chief financial officer (“CFO”), we have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15(d)-15(e) of the Exchange Act as of the end of the period covered by this Report. Based on that evaluation, our CEO and CFO have concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosures.  

 

22

Table of Contents

Management’s Report on Internal Control over Financial Reporting 

 

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our management evaluated the effectiveness of our internal control over financial reporting as of December 31, 2018.September 30, 2019. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in “Internal Control - Integrated Framework” (2013 Framework). Based on that assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2018.September 30, 2019. 

 

Changes to Internal Control Over Financial Reporting 

 

On April 1, 2018, the Company adopted the new revenue recognition accounting standard, “Revenue from Contracts with Customers.” As a result, we made additions and/or modifications to policies, procedures, and controls that have affected our internal control over financial reporting, including changes to accounting policies and procedures, operational processes and documentation practices.

 

25

Table of Contents

There were no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarterly periodsix months ended December 31, 2018September 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.  

 

Limitations on the Effectiveness of Controls 

 

Our management, including our CEO and CFO, do not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. 

 

The inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistakes. Controls can also be circumvented by the individual acts of some persons, or by collusion of two or more people. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 

 

This Form 10-Q should be read in conjunction with Item 9A “Controls and Procedures” of the Company’s Form 10-K for the fiscal year ended March 31, 2018,2019, filed June 15, 2018.July 1, 2019.

 

2326

Table of Contents

 

PART II.     OTHER INFORMATION

Item 1.Legal Proceedings

Legal Proceedings

 

From time to time, the Company may become partybe involved in litigation and investigations relating to lawsuitsclaims and claims that arisematters arising out of its operations in the ordinarynormal course of business relatingbusiness. 

On October 2, 2019, a shareholder of the Company, Meridian OHC Partners, LP (“Meridian”), filed a complaint in the United States District Court, District of Hawaii, against the Board of Directors seeking to employment, intellectual property,proceed derivatively on behalf of the Company.  The Company is named as a nominal defendant.  The complaint alleges, among other things, that the directors have breached their fiduciary duties, in overseeing the Company.  Meridian seeks declaratory and other matters. There were no significant legal matters outstandinginjunctive relief and an award of damages to the Company.  The case is Meridian v. Davis et al. (Cyanotech), No. 19-cv-0536 (D. Hawaii).  The probability and magnitude of any potential loss cannot be estimated at December 31, 2018. this time.

Item 1A.     Risk Factors

Risk Factors

 

For a discussion of the risk factors relating to our business, please refer to Part I, Item 1A of our Form 10-K for the year ended March 31, 2018,2019, which is incorporated by reference herein.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

Item 3.Defaults upon Senior Securities

Defaults upon Senior Securities

 

None.

Item 5.Other Information

Other Information

 

None.

 

2427

Table of Contents

 

Item 6. Exhibits

 

a)     The following exhibits are furnished with this report:

 

31.1

Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of February 13,November 12, 2019.

 

 

 

 

31.2

Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of February 13,November 12, 2019.

 

 

 

 

32

Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed as of February 13,November 12, 2019.

 

  

  

 

99.1

Press Release dated February 13,November 12, 2019.

 

 

 

 

101

The following financial statements from Cyanotech Corporation’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2018,September 30, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.

 

2528

Table of Contents

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  

  

CYANOTECH CORPORATION

  

  

(Registrant)

  

  

  

  

  

  

February 13,November 12, 2019

  

By:

/s/ MawaeGerald R. MortonCysewski, PH.D.

(Date)

  

  

MawaeGerald R. MortonCysewski, PH.D.

  

  

  

Chief Executive Officer; DirectorVice Chairman of the Board

  

  

  

  

  

  

  

  

February 13,November 12, 2019

  

By:

/s/ Brian B. Orlopp

(Date)

  

  

Brian B. Orlopp

  

  

  

Chief Financial Officer, Vice President — Finance & Administration and CFO

  

  

  

(Principal Financial and Accounting Officer)

 

2629

Table of Contents

 

EXHIBIT INDEX

 

Exhibit Number

  

Description

31.1

  

Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of February 13,November 12, 2019.

  

  

  

31.2

  

Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of February 13,November 12, 2019.

  

  

  

32

  

Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed as of February 13,November 12, 2019.

  

  

  

99.1

  

Press Release dated February 13,November 12, 2019.

  

  

  

101

  

The following financial statements from Cyanotech Corporation’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2018,September 30, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements

 

2730